Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Adverum Biotechnologies, Inc. (ADVM) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Adverum Biotechnologies, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1501756.
Total stock buying since 2014: $62,966,241.
Total stock sales since 2014: $40,318,587.
Total stock option exercises since 2014: $903,537.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 876,472 | $3,410,092 | 0 | $0 | 0 | $0 |
| 2024 | 532,064 | $2,709,653 | 0 | $0 | 0 | $0 |
| 2023 | 100,000 | $145,500 | 68,099 | $57,914 | 0 | $0 |
| 2022 | 126,925 | $120,252 | 71,983 | $77,020 | 0 | $0 |
| 2021 | 108,600 | $706,040 | 67,299 | $296,307 | 0 | $0 |
| 2020 | 25,384 | $337,492 | 183,171 | $3,408,585 | 177,758 | $832,020 |
| 2019 | 20,000 | $134,200 | 40,000 | $428,800 | 0 | $0 |
| 2015 | 0 | $0 | 768,700 | $36,049,961 | 64,800 | $71,431 |
| 2014 | 2,722,702 | $55,403,012 | 0 | $0 | 413 | $86 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-04 | 365,209 | $1,110,363 | 0 | $0 | 0 | $0 |
| 2025-03 | 174,507 | $860,509 | 0 | $0 | 0 | $0 |
| 2025-02 | 336,756 | $1,439,220 | 0 | $0 | 0 | $0 |
| 2024-07 | 302,064 | $2,399,153 | 0 | $0 | 0 | $0 |
| 2024-02 | 230,000 | $310,500 | 0 | $0 | 0 | $0 |
| 2023-09 | 0 | $0 | 6,201 | $9,512 | 0 | $0 |
| 2023-06 | 100,000 | $145,500 | 0 | $0 | 0 | $0 |
| 2023-03 | 0 | $0 | 61,898 | $48,402 | 0 | $0 |
| 2022-09 | 0 | $0 | 71,983 | $77,020 | 0 | $0 |
| 2022-05 | 80,000 | $67,480 | 0 | $0 | 0 | $0 |
| 2022-04 | 46,925 | $52,772 | 0 | $0 | 0 | $0 |
| 2021-12 | 50,000 | $93,358 | 0 | $0 | 0 | $0 |
| 2021-11 | 0 | $0 | 50,000 | $109,000 | 0 | $0 |
| 2021-09 | 0 | $0 | 4,766 | $10,342 | 0 | $0 |
| 2021-03 | 40,000 | $398,320 | 0 | $0 | 0 | $0 |
| 2021-02 | 0 | $0 | 12,533 | $176,965 | 0 | $0 |
| 2021-01 | 18,600 | $214,362 | 0 | $0 | 0 | $0 |
| 2020-08 | 15,384 | $199,992 | 0 | $0 | 0 | $0 |
| 2020-07 | 0 | $0 | 5,000 | $87,980 | 5,000 | $24,000 |
| 2020-06 | 0 | $0 | 58,171 | $1,425,534 | 45,000 | $215,999 |
| 2020-05 | 0 | $0 | 65,000 | $1,256,577 | 88,334 | $436,003 |
| 2020-03 | 0 | $0 | 40,000 | $406,649 | 24,424 | $84,018 |
| 2020-02 | 10,000 | $137,500 | 15,000 | $231,845 | 15,000 | $72,000 |
| 2019-12 | 0 | $0 | 40,000 | $428,800 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-04-23 | Leonard Braden Michael | Buy | 50,000 | 2.98 | 148,950 |
| 2025-04-22 | Leonard Braden Michael | Buy | 300,000 | 3.00 | 900,000 |
| 2025-04-02 | Leonard Braden Michael | Buy | 15,209 | 4.04 | 61,413 |
| 2025-03-31 | Leonard Braden Michael | Buy | 19,566 | 4.38 | 85,659 |
| 2025-03-27 | Leonard Braden Michael | Buy | 16,593 | 5.19 | 86,084 |
| 2025-03-26 | Leonard Braden Michael | Buy | 20,407 | 5.04 | 102,851 |
| 2025-03-20 | Leonard Braden Michael | Buy | 30,600 | 5.61 | 171,757 |
| 2025-03-19 | Leonard Braden Michael | Buy | 25,000 | 4.94 | 123,400 |
| 2025-03-18 | Leonard Braden Michael | Buy | 62,341 | 4.66 | 290,758 |
| 2025-02-28 | Leonard Braden Michael | Buy | 85,068 | 4.60 | 391,057 |
| 2025-02-27 | Leonard Braden Michael | Buy | 86,802 | 4.46 | 387,136 |
| 2025-02-26 | Leonard Braden Michael | Buy | 164,886 | 4.01 | 661,027 |
| 2024-07-30 | Leonard Braden Michael | Buy | 85,800 | 7.15 | 613,470 |
| 2024-07-18 | Leonard Braden Michael | Buy | 80,718 | 9.12 | 735,744 |
| 2024-07-17 | Leonard Braden Michael | Buy | 135,546 | 7.75 | 1,049,939 |
| 2024-02-07 | Lupher, Jr. Mark L. | Buy | 130,000 | 1.35 | 175,500 |
| 2024-02-07 | Scopa James Paul | Buy | 100,000 | 1.35 | 135,000 |
| 2023-09-15 | Seyedkazemi Setareh (Chief Development Officer) | Sale | 6,201 | 1.53 | 9,512 |
| 2023-06-07 | Rubinstein Linda M (Chief Financial Officer) | Buy | 100,000 | 1.46 | 145,500 |
| 2023-03-15 | Riley Brigit (Chief Scientific Officer) | Sale | 7,299 | .78 | 5,707 |
| 2023-03-15 | Soparkar Peter (Chief Operating Officer) | Sale | 13,360 | .78 | 10,447 |
| 2023-03-15 | Fischer Laurent (CEO, President and Director) | Sale | 41,239 | .78 | 32,248 |
| 2022-09-19 | Beckman Richard (Chief Medical Officer) | Sale | 4,272 | 1.07 | 4,571 |
| 2022-09-19 | Seyedkazemi Setareh (Chief Development Officer) | Sale | 6,058 | 1.07 | 6,482 |
| 2022-09-19 | Riley Brigit (Chief Scientific Officer) | Sale | 7,266 | 1.07 | 7,774 |
| 2022-09-19 | Soparkar Peter (See Remarks section) | Sale | 13,305 | 1.07 | 14,236 |
| 2022-09-19 | Fischer Laurent (CEO, President and Director) | Sale | 41,082 | 1.07 | 43,957 |
| 2022-05-23 | Seyedkazemi Setareh (Chief Development Officer) | Buy | 20,000 | .84 | 16,800 |
| 2022-05-17 | Beckman Richard (Chief Medical Officer) | Buy | 10,000 | .82 | 8,230 |
| 2022-05-17 | D'souza Rupert (Chief Financial Officer) | Buy | 10,000 | .83 | 8,270 |
| 2022-05-16 | Svoronos Dawn (Director) | Buy | 30,000 | .85 | 25,590 |
| 2022-05-13 | D'souza Rupert (Chief Financial Officer) | Buy | 10,000 | .86 | 8,590 |
| 2022-04-20 | Fischer Laurent (CEO, President and Director) | Buy | 25,000 | 1.11 | 27,800 |
| 2022-04-19 | Soparkar Peter (See Remarks section) | Buy | 21,925 | 1.14 | 24,972 |
| 2021-12-09 | Fischer Laurent (CEO, President and Director) | Buy | 14,323 | 1.85 | 26,497 |
| 2021-12-08 | Soparkar Peter (See Remarks section) | Buy | 25,000 | 1.91 | 47,750 |
| 2021-12-08 | Fischer Laurent (CEO, President and Director) | Buy | 10,677 | 1.79 | 19,111 |
| 2021-11-15 | Scopa James Paul (Director) | Sale | 50,000 | 2.18 | 109,000 |
| 2021-09-30 | Clark Julie (Chief Medical Officer) | Sale | 4,766 | 2.17 | 10,342 |
| 2021-03-31 | Svoronos Dawn (Director) | Buy | 20,000 | 10.02 | 200,340 |
| 2021-03-24 | Fischer Laurent (CEO and Director) | Buy | 10,000 | 9.88 | 98,780 |
| 2021-03-24 | Machado Patrick (Director) | Buy | 10,000 | 9.92 | 99,200 |
| 2021-02-09 | Patterson Leone D (President and CFO) | Sale | 12,533 | 14.12 | 176,965 |
| 2021-01-15 | Fischer Laurent (CEO and Director) | Buy | 8,600 | 11.53 | 99,192 |
| 2021-01-15 | Machado Patrick (Director) | Buy | 10,000 | 11.52 | 115,170 |
| 2020-08-17 | Soparkar Peter (Chief Legal Officer) | Buy | 7,692 | 13.00 | 99,996 |
| 2020-08-17 | Fischer Laurent (CEO and Director) | Buy | 7,692 | 13.00 | 99,996 |
| 2020-07-20 | Gasmi Mehdi (Director) | Sale | 5,000 | 17.60 | 87,980 |
| 2020-07-20 | Gasmi Mehdi (Director) | Option Ex | 5,000 | 4.80 | 24,000 |
| 2020-06-22 | Gasmi Mehdi (Director) | Sale | 23,605 | 25.06 | 591,612 |
| 2020-06-22 | Gasmi Mehdi (Director) | Option Ex | 23,605 | 4.80 | 113,304 |
| 2020-06-18 | Gasmi Mehdi (Director) | Sale | 11,127 | 25.01 | 278,330 |
| 2020-06-18 | Gasmi Mehdi (Director) | Option Ex | 11,127 | 4.80 | 53,409 |
| 2020-06-17 | Gasmi Mehdi (Director) | Sale | 268 | 25.01 | 6,702 |
| 2020-06-17 | Gasmi Mehdi (Director) | Option Ex | 268 | 4.80 | 1,286 |
| 2020-06-16 | Patterson Leone D (President) | Sale | 13,171 | 24.68 | 325,060 |
| 2020-06-15 | Gasmi Mehdi (Director) | Sale | 10,000 | 22.38 | 223,830 |
| 2020-06-15 | Gasmi Mehdi (Director) | Option Ex | 10,000 | 4.80 | 48,000 |
| 2020-05-21 | Gasmi Mehdi (Director) | Sale | 3,599 | 20.02 | 72,048 |
| 2020-05-21 | Gasmi Mehdi (Director) | Option Ex | 3,599 | 4.80 | 17,275 |
| 2020-05-20 | Gasmi Mehdi (Director) | Sale | 1,401 | 20.01 | 28,029 |
| 2020-05-20 | Gasmi Mehdi (Director) | Option Ex | 1,401 | 4.80 | 6,724 |
| 2020-05-18 | Gasmi Mehdi (Director) | Sale | 5,000 | 18.57 | 92,855 |
| 2020-05-18 | Gasmi Mehdi (Director) | Option Ex | 5,000 | 4.80 | 24,000 |
| 2020-05-06 | Gasmi Mehdi (Director) | Sale | 25,000 | 20.03 | 500,675 |
| 2020-05-06 | Gasmi Mehdi (Director) | Option Ex | 25,000 | 4.80 | 120,000 |
| 2020-05-06 | Patterson Leone D (CEO, President and Director) | Sale | 20,000 | 20.02 | 400,400 |
| 2020-05-06 | Patterson Leone D (CEO, President and Director) | Option Ex | 20,000 | 3.44 | 68,800 |
| 2020-05-05 | Gasmi Mehdi (Director) | Sale | 10,000 | 16.26 | 162,570 |
| 2020-05-05 | Gasmi Mehdi (Director) | Option Ex | 10,000 | 4.80 | 48,000 |
| 2020-05-04 | Scopa James Paul (Director) | Option Ex | 23,334 | 6.48 | 151,204 |
| 2020-03-20 | Patterson Leone D (CEO, President and Director) | Sale | 39,526 | 10.17 | 401,900 |
| 2020-03-20 | Patterson Leone D (CEO, President and Director) | Option Ex | 24,424 | 3.44 | 84,018 |
| 2020-03-17 | Patterson Leone D (CEO, President and Director) | Sale | 474 | 10.02 | 4,749 |
| 2020-02-18 | Gasmi Mehdi (Director) | Sale | 5,000 | 16.23 | 81,155 |
| 2020-02-18 | Gasmi Mehdi (Director) | Option Ex | 5,000 | 4.80 | 24,000 |
| 2020-02-14 | Scopa James Paul (Director) | Buy | 10,000 | 13.75 | 137,500 |
| 2020-02-12 | Gasmi Mehdi (Director) | Sale | 10,000 | 15.07 | 150,690 |
| 2020-02-12 | Gasmi Mehdi (Director) | Option Ex | 10,000 | 4.80 | 48,000 |
| 2019-12-23 | Patterson Leone D (CEO, President and Director) | Sale | 40,000 | 10.72 | 428,800 |
| 2019-05-06 | Scopa James Paul (Director) | Buy | 20,000 | 6.71 | 134,200 |
| 2015-06-15 | Schwartz Steven Daniel (Director) | Sale | 16,875 | 39.86 | 672,671 |
| 2015-06-15 | Gasmi Mehdi (SVP,Pharmaceutical Development) | Sale | 500 | 39.86 | 19,931 |
| 2015-06-15 | Gasmi Mehdi (SVP,Pharmaceutical Development) | Option Ex | 500 | 2.75 | 1,375 |
| 2015-06-15 | Wachter Paul (Director) | Sale | 1,192 | 39.86 | 47,515 |
| 2015-06-12 | Hull Hans (SVP, Business Operations) | Option Ex | 8,300 | .19 | 1,577 |
| 2015-06-12 | Bain Linda (Chief Financial Officer) | Sale | 3,500 | 39.94 | 139,793 |
| 2015-06-12 | Bain Linda (Chief Financial Officer) | Option Ex | 3,500 | 3.15 | 11,025 |
| 2015-06-11 | Blumenkranz Mark S. (Director) | Sale | 1,900 | 39.97 | 75,939 |
| 2015-06-10 | Chalberg Thomas W. (Chief Executive Officer) | Sale | 25,000 | 37.94 | 948,575 |
| 2015-06-10 | Blumenkranz Mark S. (Director) | Sale | 600 | 39.91 | 23,947 |
| 2015-06-10 | Guerin John Patrick Et Al (Director) | Sale | 699 | 206.00 | 143,994 |
| 2015-06-09 | Blumenkranz Mark S. (Director) | Sale | 22,500 | 36.36 | 818,032 |
| 2015-06-08 | Gasmi Mehdi (VP, Pharmaceutical Development) | Sale | 500 | 38.93 | 19,467 |
| 2015-06-08 | Gasmi Mehdi (VP, Pharmaceutical Development) | Option Ex | 500 | 2.75 | 1,375 |
| 2015-06-08 | Wachter Paul (Director) | Sale | 1,192 | 38.93 | 46,409 |
| 2015-06-05 | Blumenkranz Mark S. (Director) | Sale | 5,000 | 40.08 | 200,415 |
| 2015-06-04 | Hull Hans (SVP, Business Operations) | Sale | 2,000 | 37.64 | 75,284 |
| 2015-06-04 | Hull Hans (SVP, Business Operations) | Option Ex | 2,000 | .19 | 380 |
| 2015-06-01 | Schwartz Steven Daniel (Director) | Sale | 17,250 | 36.46 | 628,917 |
| 2015-06-01 | Wachter Paul (Director) | Sale | 1,192 | 36.46 | 43,461 |
| 2015-05-28 | Gasmi Mehdi (VP, Pharmaceutical Development) | Sale | 500 | 38.02 | 19,009 |
| 2015-05-28 | Gasmi Mehdi (VP, Pharmaceutical Development) | Option Ex | 500 | 2.75 | 1,375 |
| 2015-05-28 | Guerin John Patrick Et Al (Director) | Sale | 1 | 208.00 | 208 |
| 2015-05-27 | Guerin John Patrick Et Al (Director) | Sale | 1,205 | 206.00 | 248,230 |
| 2015-05-26 | Wachter Paul (Director) | Sale | 1,192 | 37.47 | 44,663 |
| 2015-05-22 | Schwartz Steven Daniel (Director) | Sale | 16,875 | 38.52 | 650,041 |
| 2015-05-21 | Gasmi Mehdi (VP, Pharmaceutical Development) | Sale | 500 | 38.87 | 19,435 |
| 2015-05-21 | Gasmi Mehdi (VP, Pharmaceutical Development) | Option Ex | 500 | 2.75 | 1,375 |
| 2015-05-19 | Blumenkranz Mark S. (Director) | Sale | 3,000 | 36.91 | 110,733 |
| 2015-05-18 | Wachter Paul (Director) | Sale | 1,192 | 35.31 | 42,085 |
| 2015-05-15 | Blumenkranz Mark S. (Director) | Sale | 22,500 | 35.68 | 802,800 |
| 2015-05-14 | Gasmi Mehdi (VP, Pharmaceutical Development) | Sale | 500 | 35.31 | 17,656 |
| 2015-05-14 | Gasmi Mehdi (VP, Pharmaceutical Development) | Option Ex | 500 | 2.75 | 1,375 |
| 2015-05-13 | Blumenkranz Mark S. (Director) | Sale | 715 | 34.94 | 24,984 |
| 2015-05-13 | Bain Linda (Chief Financial Officer) | Sale | 285 | 34.94 | 9,958 |
| 2015-05-13 | Bain Linda (Chief Financial Officer) | Option Ex | 285 | 3.15 | 897 |
| 2015-05-11 | Blumenkranz Mark S. (Director) | Sale | 1,785 | 34.91 | 62,323 |
| 2015-05-11 | Bain Linda (Chief Financial Officer) | Sale | 715 | 34.91 | 24,964 |
| 2015-05-11 | Bain Linda (Chief Financial Officer) | Option Ex | 715 | 3.15 | 2,252 |
| 2015-05-11 | Wachter Paul (Director) | Sale | 1,192 | 33.60 | 40,048 |
| 2015-05-08 | Schwartz Steven Daniel (Director) | Sale | 17,250 | 33.05 | 570,095 |
| 2015-05-07 | Gasmi Mehdi (VP, Pharmaceutical Development) | Sale | 500 | 33.28 | 16,638 |
| 2015-05-07 | Gasmi Mehdi (VP, Pharmaceutical Development) | Option Ex | 500 | 2.75 | 1,375 |
| 2015-05-05 | Chalberg Thomas W. (Chief Executive Officer) | Sale | 25,000 | 30.00 | 750,100 |
| 2015-05-04 | Hull Hans (SVP, Business Operations) | Sale | 5,000 | 30.87 | 154,350 |
| 2015-05-04 | Hull Hans (SVP, Business Operations) | Option Ex | 5,000 | .19 | 950 |
| 2015-05-04 | Bain Linda (Chief Financial Officer) | Sale | 2,500 | 31.59 | 78,972 |
| 2015-05-04 | Bain Linda (Chief Financial Officer) | Option Ex | 2,500 | 3.15 | 7,875 |
| 2015-05-04 | Wachter Paul (Director) | Sale | 1,192 | 30.87 | 36,797 |
| 2015-05-01 | Blumenkranz Mark S. (Director) | Sale | 20,000 | 32.37 | 647,300 |
| 2015-04-28 | Gasmi Mehdi (VP, Pharmaceutical Development) | Sale | 1,000 | 35.67 | 35,667 |
| 2015-04-28 | Gasmi Mehdi (VP, Pharmaceutical Development) | Option Ex | 1,000 | 2.75 | 2,750 |
| 2015-04-27 | Wachter Paul (Director) | Sale | 1,192 | 35.61 | 42,443 |
| 2015-04-23 | Schwartz Steven Daniel | Sale | 16,875 | 38.62 | 651,661 |
| 2015-04-21 | Gasmi Mehdi (VP, Pharmaceutical Development) | Sale | 1,000 | 39.21 | 39,211 |
| 2015-04-21 | Gasmi Mehdi (VP, Pharmaceutical Development) | Option Ex | 1,000 | 2.75 | 2,750 |
| 2015-04-20 | Wachter Paul | Sale | 1,192 | 40.19 | 47,910 |
| 2015-04-16 | Blumenkranz Mark S. | Sale | 25,000 | 41.81 | 1,045,325 |
| 2015-04-14 | Zygtech, Llc | Sale | 4,600 | 39.93 | 183,664 |
| 2015-04-14 | Gasmi Mehdi (VP, Pharmaceutical Development) | Sale | 1,000 | 39.45 | 39,448 |
| 2015-04-14 | Gasmi Mehdi (VP, Pharmaceutical Development) | Option Ex | 1,000 | 2.75 | 2,750 |
| 2015-04-13 | Zygtech, Llc | Sale | 20,400 | 39.91 | 814,184 |
| 2015-04-13 | Wachter Paul | Sale | 1,192 | 39.89 | 47,553 |
| 2015-04-09 | Schwartz Steven Daniel | Sale | 17,250 | 40.05 | 690,828 |
| 2015-04-08 | Blumenkranz Mark S. | Sale | 2,500 | 39.94 | 99,840 |
| 2015-04-07 | Hull Hans (SVP, Business Operations) | Sale | 27,500 | 38.82 | 1,067,660 |
| 2015-04-07 | Hull Hans (SVP, Business Operations) | Option Ex | 27,500 | .19 | 5,225 |
| 2015-04-07 | Gasmi Mehdi (VP, Pharmaceutical Development) | Sale | 9,000 | 38.82 | 349,416 |
| 2015-04-07 | Gasmi Mehdi (VP, Pharmaceutical Development) | Option Ex | 9,000 | 2.75 | 24,750 |
| 2015-04-07 | Blumenkranz Mark S. | Sale | 25,500 | 38.82 | 990,012 |
| 2015-01-13 | Schwartz Steven Daniel | Sale | 91,000 | 55.46 | 5,046,860 |
| 2015-01-13 | Zygtech, Llc | Sale | 100,000 | 55.46 | 5,546,000 |
| 2015-01-13 | Chalberg Thomas W. (Chief Executive Officer) | Sale | 85,000 | 55.46 | 4,714,100 |
| 2015-01-13 | Blumenkranz Mark S. | Sale | 100,000 | 55.46 | 5,546,000 |
| 2015-01-13 | Wachter Paul | Sale | 14,000 | 55.46 | 776,440 |
| 2014-12-12 | Chalberg Thomas W. (Chief Executive Officer) | Option Ex | 413 | .21 | 86 |
| 2014-08-05 | Koh Bong Y (10% Owner) | Buy | 400,000 | 17.00 | 6,800,000 |
| 2014-08-05 | Vhcp Management Ii, Llc (10% Owner) | Buy | 400,000 | 17.00 | 6,800,000 |
| 2014-08-05 | Deerfield International Master Fund, L.p. | Buy | 1,334,467 | 23.83 | 31,803,017 |
| 2014-08-05 | Regeneron Pharmaceuticals Inc (10% Owner) | Buy | 588,235 | 17.00 | 9,999,995 |
Insider trading activities including stock purchases, stock sales, and option exercises of ADVM listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Adverum Biotechnologies, Inc. (symbol ADVM, CIK number 1501756) see the Securities and Exchange Commission (SEC) website.